Scienza e Tecnologia
HanAll Biopharma Announces First Quarter 2021 Results
The growth of R&D revenue including milestone payments from HL161 and HL036 licensed to Immunovant and Harbour BioMed was a main performance driver while domestic drug sales slightly increased year-on-year. HanAll remain committed to delivering innovative medicines for patients with its improved financial performance.
The company plans to start the second Phase 3 clinical trial in dry eye disease (DED) in the 2H of 2021, which is being co-developed with Daewoong Pharmaceutical.
Meanwhile, HanAll has recently appointed David Hernandez , former Head of Clinical Operations Japan at Merck Biopharma, as Vice President of Clinical Operations at HPI, a U.S. subsidiary of HanAll, to accelerate clinical trials of its current and future pipeline compounds.
HanAll Biopharma is a global biopharmaceutical company founded in 1973 with a mission to promote human health. HanAll has been delivering a portfolio of pharmaceutical products in areas of endocrine, circulatory, and urologic diseases for more than 47 years. HanAll is focused on discovering and developing innovative medicines for people suffering with diseases in which there are no effective treatments. Its a leading pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody drug, is in Phase 2 trials in 5 rare autoimmune disorders across the world. Another main candidate, HL036 (INN: tanfanercept), an anti-TNF protein drug, for the treatment of dry eye disease is in Phase 3 clinical trials in the U.S. and China .
HanAll IR team (ir@hanall.co.kr) or
Daewoong IR team (t_797rx@daewoong.co.kr)